Chinese biotechnology company Hanx Biopharmaceuticals Co Ltd announced on Thursday the first patient dosing in Australia on 30 December 2024 for the Phase 1 clinical trial of HX044 in patients with advanced solid tumours.
HX044 is an innovative bispecific antibody independently developed by Hanx Biopharmaceuticals. It is a first-in-class and considered to be a next generation immune-checkpoint inhibitor designed to treat a wide range of malignant tumours, including PD-1-resistant solid tumours such as non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma and gastrointestinal cancers.
According to Hanx Biopharmaceuticals, HX044 represents a new generation CTLA-4 immunotherapy by expanding the therapeutic window, optimising safety and enhancing antitumour immune responses, showcasing a breakthrough in CTLA-4 immunotherapy.
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
ANGLE plc reports successful dual CTC-DNA and ctDNA analysis using Illumina platform
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Vast Therapeutics receives USD2m grant from National Institutes of Health
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
bioAffinity Technologies declares successful beta launch of CyPath Lung in Texas